Twenty-four-hour hemodynamic profile during treatment of essential hypertension by once-a-day nadolol

Extreme changes in dietary sodium effect daily variability and level of blood pressure in borderline hypertensive patients

This study examined the effect of large changes in dietary sodium on the average ambulatory blood pressure and its variability in 19 patients with uncomplicated borderline hypertension. Each patient participated in a 16-week protocol that consisted of four 4-week periods of different sodium intake (medium (120-160 mEq/day) during periods 1 and 3 and low (< 40 mEq/day) or high (> 225 mEq/day) during either period 2 or 4. The 24-hour urine sodium during the low and high periods averaged 18 and 327 mEq/day, respectively. Ambulatory blood pressure monitoring was done at the end of the fourth week of the low and high diet periods. During monitoring, pressures were recorded every 15 minutes while awake; in addition, patients kept diaries noting activities, posture, and situation at each measurement. The results show that there was a decline of 16/7 mmHg in the average ambulatory awake systolic and diastolic pressures from the high sodium to low sodium diets. Corresponding casual pressures decreased an average of 15 and 8 mmHg, respectively. In examining the factors associated with ambulatory pressure variability, systolic pressure showed greater variation by activity on a low sodium diet than on the high. The findings suggest that sodium restriction has a variable, but in some cases marked, effect on lowering the ambulatory blood pressure in borderline mildly hypertensive patients and that sodium balance may be important to consider when examining ambulatory blood pressure variability. © 1994 Wiley-Liss, Inc.

Beta-blocker duration of action and implications for therapy

Two studies were conducted to measure the effect of serum half-life on beta-blocker-related heart rate reduction throughout the 24-hour period. In the first study, nadolol, atenolol and pindolol were associated with significant (p less than 0.01) heart rate reduction even at 24 hours after dose. Nadolol, with a plasma half-life of 15.5 hours, had the most pronounced heart rate-lowering effect 24 hours after the daily dose compared to pindolol, which had a half-life of 5.5 hours. In a randomized, double-blind, crossover study, nadolol and atenolol had similar effects 3 to 4 hours after the daily dose. Nadolol, however, produced greater suppression of heart rate and double product (blood pressure x heart rate) than atenolol (compared to placebo) 24 hours after ingestion of the daily dose. On ambulatory electrocardiography 24 hours after medication administration, 80 to 100% of the heart rate-attenuating effect of nadolol was maintained versus only 20 to 45% of atenolol's effect. Statistically significant (p less than 0.05) reductions in heart rate were produced by nadolol, but not by atenolol, between 4 and 5 A.M., 6 and 7 A.M., 8 and 9 A.M. and 9 and 10 A.M. Furthermore, nadolol remained at 52% of peak blood level at 24 hours, whereas atenolol was at 20%. The data from these 2 studies indicate that significant differences in duration of action exist between beta blockers.

Loss of nocturnal decline in blood pressure after cardiac transplantation

Twenty-four hour noninvasive ambulatory blood pressure and heart rate monitoring was performed on patients who underwent orthotopic cardiac transplantation, as part of the investigation of the de novo hypertension that developes in such patients. Patients with essential hypertension served as control subjects. The results demonstrated a highly significant loss of the usual decline in blood pressure and heart rate during sleep in the transplant patients. A similar loss of nocturnal decline in blood pressure was noted in a group of 10 patients with autonomic neuropathy secondary to diabetes mellitus. The de novo hypertension associated with cardiac transplantation is probably multicausal. Impairment of renal function by cyclosporin-A with associated salt and water retention and persistent elevation of the systemic vascular resistance in the presence of a restored normal cardiac output by the "new" heart are major factors. In addition, loss of the normal nocturnal decline in blood pressure and heart rate, which probably is related to the denervated state of the transplanted heart, may play an important role in blood pressure control.

Twenty-four-hour blood pressure profile and blood pressure variability in untreated hypertension and during antihypertensive treatment by once-a-day nadolol

First, blood pressure and heart rate variability was studied in 89 normotensive and hypertensive ambulatory subjects with the use of an intra-arterial monitoring device. Short- and long-term variabilities were analyzed by computer. Absolute variabilities (standard deviations) were greatest in patients with hypertension, but relative variabilities (variation coefficients, i.e., standard deviations as percent of means) were slightly lower in the subjects with more severe hypertension. Second, the effect of nadolol on 24-hour blood pressure and heart rate values and on their variability was assessed in seven ambulatory patients with essential hypertension by means of the same intra-arterial device and computer analysis. Two recording sessions were performed (1) without treatment and (2) after 10 days' administration of nadolol once a day (dose range, 80 to 320 mg). Nadolol, given once a day, was shown to reduce blood pressure uniformly throughout the 24-hour period without loss of activity in the hours farthest from administration. The lack of alteration in relative blood pressure variability suggests that nadolol lowers blood pressure without interfering with the mechanisms involved in cardiovascular homeostasis. Reduction in heart rate variability after nadolol suggests less chance of tachycardia episodes in patients with angina and/or arrhythmias receiving nadolol.